Online inquiry

IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3183MR)

This product GTTS-WQ3183MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANPEP gene. The antibody can be applied in Mesothelioma, Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001150.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 290
UniProt ID P15144
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3183MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8733MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ13332MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ4008MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ14750MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ10032MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ12715MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ9536MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ552MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 4D5-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW